Ashland Inc. (ASH)
$
64.16
+1.03 (1.61%)
Key metrics
Financial statements
Free cash flow per share
6.2833
Market cap
2.9 Billion
Price to sales ratio
1.6258
Debt to equity
0.7929
Current ratio
3.1530
Income quality
-0.2558
Average inventory
566 Million
ROE
-0.3365
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ashland Inc. operates globally, providing a diverse range of additives and specialty ingredients through multiple segments including Life Sciences, Personal Care & Household, Specialty Additives, and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical solutions such as controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders. It also focuses on nutrition solutions that include thickeners, stabilizers, emulsifiers, and various additives. Furthermore, the nutraceutical solutions they offer cater to areas like weight management, joint comfort, digestive health, sports nutrition, and general wellness, alongside custom formulation, toll processing, and particle engineering services. In the Personal Care & Household segment, Ashland provides a comprehensive assortment of nature-based, biodegradable, and performance-enhancing ingredients suitable for toothpaste, mouthwashes, denture cleaning, and overall dental care. This segment also includes nature-derived rheology ingredients and biodegradable surface wetting agents for household products. The Specialty Additives segment focuses on delivering rheology modifiers, foam control agents, surfactants, and pH neutralizers, along with advanced ceramics utilized in catalytic converters and environmental filters. The Intermediates and Solvents segment produces 1,4 butanediol and its derivatives, including n-methylpyrrolidone, serving various consumer and industrial markets such as architectural coatings, energy, and pharmaceuticals. The company recorded an operating income of -$775,000,000.00 reflecting its earnings from core operations, and reported a substantial revenue of $1,824,000,000.00 demonstrating its strong market presence. Moreover, the income before tax amounted to -$809,000,000.00 showcasing its pre-tax profitability, while the net income ratio is -$0.46 indicating the company's profitability margin. The net total of other income and expenses is -$34,000,000.00 reflecting non-core financial activities. Ashland Inc. is positioned to appeal to investors due to its reasonably priced stock at $49.74 which draws interest from a broad array of market participants. Despite this, the stock has a low average trading volume of $817,322.00 suggesting reduced market activity. With a mid-range market capitalization of $2,936,115,007.00 the company is recognized as a steady performer in its field. It is a key player in the $Chemicals - Specialty industry, significantly impacting the overall market landscape, and belongs to the $Basic Materials sector, where it continues to drive innovation and growth.
Is Ashland Inc. (ASH) a good investment?
Investing in Ashland Inc. (ASH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Ashland Inc. (ASH)'s stock forecast?
Analysts predict Ashland Inc. stock to fluctuate between $45.21 (low) and $67.39 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ashland Inc.'s market capitalization?
As of 2026-02-06, Ashland Inc.'s market cap is $2,936,115,007, based on 45,762,391 outstanding shares.
How does Ashland Inc. compare to competitors like Southern Copper Corporation?
Compared to Southern Copper Corporation, Ashland Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Ashland Inc. pay dividends?
Ashland Inc. pays dividends. The current dividend yield is 2.59%, with a payout of $0.42 per share.
How can I buy Ashland Inc. (ASH) stock?
To buy Ashland Inc. (ASH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ASH. Place an order (Market, Limit, etc.).
What is the best time to invest in Ashland Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Ashland Inc. stock ever split?
Ashland Inc.'s last stock split was 511:250 on 2017-05-15.
How did Ashland Inc. perform in the last earnings report?
Revenue: $1,824,000,000 | EPS: -$18.37 | Growth: -632.46%.
Where can I find Ashland Inc.'s investor relations reports?
Visit https://www.ashland.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ashland Inc.?
You can explore historical data from here
What is the all-time high and low for Ashland Inc. stock?
All-time high: $114.36 (2022-12-02) | All-time low: $45.21 (2025-04-09).
What are the key trends affecting Ashland Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Ashland Inc. (ASH) Q1 2026 Earnings Call Transcript
zacks.com
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Ashland (ASH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.
globenewswire.com
Sales of $386 million, down five percent from the prior-year quarter Previously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percent Loss from continuing operations of $14 million, or $(0.30) per diluted share Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted share Net loss of $12 million, or $(0.26) per diluted share Adjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca divestiture, Adjusted EBITDA declined three percent Cash flows provided by operating activities of $125 million; Ongoing Free Cash Flow2 of $26 million Narrowing full‑year fiscal 2026 Adjusted EBITDA guidance to $400–$420 million, reflecting approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions, isolated to the second quarter WILMINGTON, Del., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the first quarter of fiscal year 2026, which ended December 31, 2025, and narrowed its full-year fiscal 2026 outlook.
globenewswire.com
WILMINGTON, Del., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2026 earnings release at approximately 5 p.m.
globenewswire.com
WILMINGTON, Del., Jan. 19, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock.
seekingalpha.com
Lyell Immunopharma (LYEL) has surged 191% YTD, driven by strong momentum and promising CAR T-cell therapy pipeline candidates LYL314 and LYL273. LYL314 achieved a 93% overall response and 76% complete response rate in heavily pre-treated LBCL, positioning LYEL as a differentiated player in CAR T therapies. LYEL maintains a $320 million cash position, funding operations into 2027, with pivotal LYL314 trial data and a BLA submission targeted for 2027.
globenewswire.com
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ASH Annual meeting in Florida this past week. The independent study authors concluded that remestemcel-L showed superior outcomes in complete and overall remission compared with ruxolitinib.1
globenewswire.com
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), primary central nervous system lymphoma (PCNSL), and diffuse large B-cell lymphoma (DLBCL).
globenewswire.com
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company's novel drug, in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. This presentation provided an update on the results released in an oral presentation at ASH 2024 and featured data from a longer follow-up on efficacy and safety.
See all news
